HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation.

Abstract
We evaluated the levels and distribution of hypoxia in 31 human tumors using fluorescent immunohistochemical detection of binding by the 2-nitroimidazole, EF5. Hypoxia was found to be a heterogeneous property of human tumors. Necrosis was usually found adjacent to the highest level of binding in an individual patient's tumor. However, hypoxia often occurred without necrosis. In the group of tumors studied, the most common relationship between blood vessels (PECAM/CD31) and EF5 staining was consistent with diffusion-limited hypoxia; acute hypoxia occurred infrequently. Within a given patient's tumor, there was an inverse correlation between regions of proliferation (Ki-67) and regions of hypoxia. Again, however, when these parameters were examined in a group of patients, the absence of proliferation did not predict the presence of hypoxia. The relationships between hypoxia and other biologic endpoints are complex, but, within a given tumor's spatial relationships, they are in accord with known physiologic principles. Thus, our data emphasize that the relationships between hypoxia and other biologic parameters vary between patients. Necrosis, proliferation, and blood vessel distribution cannot predict the level or presence of hypoxia in an individual patient's tumor.
AuthorsS M Evans, S M Hahn, D P Magarelli, C J Koch
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 24 Issue 5 Pg. 467-72 (Oct 2001) ISSN: 0277-3732 [Print] United States
PMID11586098 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Hydrocarbons, Fluorinated
  • Indicators and Reagents
  • Etanidazole
  • 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide
Topics
  • Antineoplastic Agents
  • Cell Division
  • Cell Hypoxia
  • Clinical Trials, Phase I as Topic
  • Etanidazole (analogs & derivatives, metabolism)
  • Humans
  • Hydrocarbons, Fluorinated (metabolism)
  • Immunohistochemistry
  • Indicators and Reagents
  • Necrosis
  • Neoplasms (blood supply, metabolism, pathology)
  • Neovascularization, Pathologic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: